Alnylam Pharmaceuticals, Inc. ALNY
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. 10-K, Item 1
- Employees
- 2,500
- Headquarters
- Cambridge, MA
- CEO
- Yvonne Greenstreet
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $3.7B through the costs to a net profit of $313.7M · income statement of the 10-K
ALNY among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
53 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 12, 2026 against Feb 13, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +91.8% ($405.3M to $777.6M) vs revenue +65.2% ($2.2B to $3.7B), +26.7 pts apart
-
Cash from operations $524.1M vs net income $313.7M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +5.4% ($78.5M to $82.7M) vs revenue +65.2% ($2.2B to $3.7B), -59.8 pts apart
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Liability Related to Sale of Future Royalties - Leqvio
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
53 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
If we are unable to sustain and grow revenues from sales of AMVUTTRA, our business would be materially harmed, our future operating results would be adversely impacted, and the market price of our common stock would likely decline. In 2025, a significant portion of our net product revenues was derived from the sale of our TTR products,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
We may have difficulty continuing to expand our global operations successfully at the scale necessary to support our Alnylam 2030 ambitions.
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Any funding, personnel, policy or other disruptions at the FDA and other agencies may also delay those agencies’ review and response to our or our collaborators’ regulatory submissions, which would adversely affect our business. For example, over
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Our six marketed products, including two products that are commercialized by collaborators, and any product candidates for which we or our collaborators may ultimately receive marketing authorization, are subject to ongoing regulatory
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.0B | $1.8B | $2.2B | $3.7B |
| Net income | −$1.1B | −$440.2M | −$278.2M | $313.7M |
| Operating cash flow | −$541.3M | $104.2M | −$8.3M | $524.1M |
| Free cash flow | −$613.3M | $41.9M | −$42.6M | $465.4M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$3.7B ▲ 65.2% in FY2025$313.7M in FY2025$465.4M in FY2025
Recent filings
6 filings in the last 30 days · SEC EDGAR
-
BuyNov 12, 2026SCHULMAN AMY W (Director) bought $300K open-market purchase on Nov 9, 2026
-
BuyNov 12, 2026Sigal Charles Elliott (Director) bought $244K open-market purchase on Nov 10, 2026
-
8-KNov 5, 2026Director or officer change, Other events 8-K items 5.02, 8.01
-
Planned saleOct 29, 2026Tolga Tanguler (Chief Commercialization Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 22,438 shares, runs to Aug 6, 2027
-
8-KOct 29, 2026Quarterly results 8-K item 2.02
About the company
Alnylam Pharmaceuticals, Inc., Cambridge, MA · from the 10-K filed Feb 12, 2026
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics.
- Headquarters
- Cambridge, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
Employees, at the top of the page: "As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.